Government Shutdown Impacts FDA Drug Approvals

Web Exclusives - FDA Approvals, News & Updates, In the News

Now in its fourth week, the longest shutdown in the history of the federal government is having an impact on patient care, as the US Food and Drug Administration (FDA) has put drug reviews and approvals for new drugs and devices, as well as the issuance of new guidance documents, on indefinite hold. The FDA recently posted on its website a notice alerting the public of its current operational status.

While about 75% of federal agencies had secured FY2019 funding prior to the political impasse, the FDA had not, and is among the agencies that faced partial shutdown. Approximately 40% of the FDA’s entire workforce has been furloughed since December 22, 2018, when the government stopped operations.

Some vital public safety functions continue, including inspection of imported drugs, but this has diverted personnel from tasks considered nonessential. Several pharmaceutical companies that had hoped for early 2019 approvals now hang in suspense, with some inside the government speculating that the political crisis may not be resolved for weeks to come. As a result of heavy backlogs, prescribers and patients will likely face extended wait times for approvals even after the restoration of the agency to its full staffing once the stalemate is broken and government business resumes.

Under the Prescription Drug User Fee Act, the FDA uses the fees collected from drug manufacturers to fund drug reviews and approvals and is currently using leftover monies to finish working on applications submitted in FY2018; however, that money is expected to run out in early February. The FDA is accepting no new testing applications or fees, and in addition, is reallocating the funds previously collected for premarket review work to prioritize postmarket safety surveillance, according to the FDA Commissioner Scott Gottlieb. With no end to the shutdown in sight, the long-term consequences on the pharmaceutical industry and patient care remain an open question.

Related Items
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Web Exclusives published on February 22, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
Web Exclusives published on February 19, 2019 in FDA Approvals, News & Updates, In the News
February 8, 2019 - FDA Approvals, News & Updates
Web Exclusives published on February 1, 2019 in FDA Approvals, News & Updates, In the News
February 1, 2019 - FDA Approvals, News & Updates
Web Exclusives published on February 1, 2019 in FDA Approvals, News & Updates, In the News
I. New Drugs
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
II. New Indications
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation
Web Exclusives published on November 30, 2018 in FDA Approvals, News & Updates
Lenvima Now Approved for Unresectable Hepatocellular Carcinoma
Web Exclusives published on November 13, 2018 in FDA Approvals, News & Updates
Last modified: February 20, 2019